Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
- Status
- TERMINATED
- Phase
- PHASE4
Clinical Trials Related to Palbociclib
Related studies linked through entity extraction aliases.
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
- Status
- UNKNOWN
- Phase
- PHASE2
Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC
- Status
- COMPLETED
- Phase
- PHASE2
Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE1
NCT Neuro Master Match - N²M² (NOA-20)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Palbociclib After CDK and Endocrine Therapy (PACE)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
- Status
- TERMINATED
- Phase
- PHASE1
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma
- Status
- COMPLETED
- Phase
- PHASE2
Biomarker-based Study in R/M SCCHN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)
- Status
- COMPLETED
- Phase
- PHASE2
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
- Status
- SUSPENDED
- Phase
- PHASE1
Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2